🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Fluoxetine (drug)

    The First People's Hospital of Lianyungang

    Hepatobiliary Malignancy

    phase 2 small molecule active

    1 trial

  2. Forxiga 10 mg film-coated tablets

    Fondazione Telethon ETS

    Chemotherapy-induced cardiotoxicity in breast cancer

    phase 2 small molecule active

    1 trial

  3. Fostamatinib Disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  4. Fresh Frozen Plasma (FFP)

    United Therapeutics Europe Ltd

    Anticoagulant Reversal

    phase 2 mab terminated

    1 trial

  5. Frexalimab, Matched Placebo for Test

    Sanofi-aventis Healthcare Pty Ltd

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  6. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  7. Full Spectrum Microbiota

    Finch Therapeutics Group

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule completed

    1 trial

  8. Fulvestrant

    United Therapeutics Europe Ltd

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Fulvestrant

    ATOSSA THERAPEUTICS, INC.

    Female Breast Carcinoma

    phase 2 small molecule terminated

    1 trial

  10. Fulvestrant with Enzalutamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  11. Functional Precision Oncology

    United Therapeutics Europe Ltd

    Breast Cancer Recurrent

    phase 2 other active

    1 trial

  12. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Furmonertinib in combination with Anrotinib and chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  15. Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372

    The George Institute

    Subjects with advanced solid tumour

    phase 2 small molecule active

    1 trial

  16. G-STROPHANTHIN , The placebo vial contains NaCl 0.9% and phosphate buffer ad 1ml corresponding to the IMP except API for intravenous administration. There are no visible differences in comparison to volume, seize, exterior, colour etc. of the investigational product.

    Lacuna Pharma Pty Ltd

    Acute Heart Failure

    phase 2 small molecule active

    1 trial

  17. G03-52-01

    United Therapeutics Europe Ltd

    Healthy

    phase 2 small molecule completed

    1 trial

  18. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  19. GC4419

    Galera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  20. GC4419

    Galera Therapeutics

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  21. GC4419 (avasopasem manganese)

    Galera Therapeutics

    Esophagitis

    phase 2 small molecule terminated

    1 trial

  22. GC4711 +SBRT

    Galera Therapeutics

    SBRT

    phase 2 small molecule terminated

    1 trial

  23. GEMCITABINE

    Wuhan Createrna Science and Technology Co., Ltd

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  24. GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources